|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 55.69 BRL | +4.70% |
|
-4.12% | -21.46% |
| 07-25 | US FDA approves Outlook Therapeutics' eye disease drug | RE |
| 07-24 | Sanofi to Drop Eczema Drug Amid Review of Pipeline Under New CEO | DJ |
| Market Cap | 66.74B 338B 58.62B 54.51B 50.02B 93.99B 6,427B 95.44B 647B 253B 3,160B 251B 245B 10,925B | P/E 2026 * |
17.3x | P/E 2027 * | 13.8x |
|---|---|---|---|---|---|
| Enterprise Value | 58.92B 298B 51.75B 48.13B 44.16B 82.98B 5,674B 84.25B 571B 223B 2,790B 221B 216B 9,645B | EV / Sales 2026 * |
3.71x | EV / Sales 2027 * | 3.19x |
| Free-Float |
72.33% | Yield 2026 * |
0.59% | Yield 2027 * | 0.67% |
Last Transcript: Regeneron Pharmaceuticals, Inc.
| 1 day | +4.70% | ||
| 1 week | -4.12% | ||
| Current month | +3.03% | ||
| 1 month | +3.98% | ||
| 3 months | -10.91% | ||
| 6 months | -16.43% | ||
| Current year | -21.46% |
| 1 week | 54.19 |  | 57.9 |
| 1 month | 53.91 | | 58.69 |
| Current year | 50 | | 73.16 |
| 1 year | 49.24 | | 73.33 |
| 3 years | 44.82 | | 111.72 |
| 5 years | 44.82 | | 111.72 |
| 10 years | 18.16 | | 111.72 |
| Manager | Title | Age | Since |
|---|---|---|---|
| President | 66 | 01/01/2001 | |
| Chief Executive Officer | 73 | 08/01/1988 | |
| Director of Finance/CFO | 55 | 05/02/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 73 | 09/06/2023 | |
Michael Brown
BRD | Director/Board Member | 85 | 01/06/1991 |
Joseph Goldstein
BRD | Director/Board Member | 85 | 01/06/1991 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.70% | -4.12% | - | - | 66.74B | |
| +1.23% | +2.80% | +38.09% | +200.66% | 53.32B | |
| +10.08% | +51.80% | +51.80% | +51.80% | 48.12B | |
| -1.32% | -7.38% | -57.37% | -56.96% | 38.25B | |
| +0.78% | -1.84% | +53.73% | -25.20% | 29.85B | |
| +0.84% | +0.36% | +67.62% | +84.46% | 23.51B | |
| -5.17% | -12.54% | +58.33% | -55.63% | 21.45B | |
| -1.21% | +1.12% | +0.90% | +164.17% | 19.97B | |
| +1.31% | +3.24% | +81.47% | +157.97% | 16.47B | |
| -0.22% | -0.95% | +62.78% | +123.12% | 16.38B | |
| Average | +1.10% | -0.30% | +39.71% | +71.60% | 29.7B | |
| Weighted average by Cap. | +2.21% | +0.83% | +34.27% | +70.88% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 15.87B 80.41B 13.94B 12.96B 11.9B 22.35B 1,529B 22.7B 154B 60.15B 751B 59.59B 58.3B 2,598B | 17.61B 89.2B 15.47B 14.38B 13.2B 24.8B 1,696B 25.18B 171B 66.72B 834B 66.1B 64.68B 2,882B |
| Net income | 3.98B 20.14B 3.49B 3.25B 2.98B 5.6B 383B 5.69B 38.57B 15.07B 188B 14.93B 14.61B 651B | 5.03B 25.46B 4.41B 4.1B 3.77B 7.08B 484B 7.19B 48.74B 19.04B 238B 18.87B 18.46B 823B |
| Net Debt | -7.82B -39.63B -6.87B -6.39B -5.86B -11.02B -753B -11.19B -75.88B -29.64B -370B -29.37B -28.73B -1,281B | -10.51B -53.26B -9.23B -8.59B -7.88B -14.81B -1,012B -15.03B -102B -39.84B -498B -39.47B -38.62B -1,721B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24/07/26 | R$55.69 | +0.81% | 223 |
| 23/07/26 | R$55.24 | -2.90% | 7 |
| 21/07/26 | R$56.89 | -1.74% | 765 |
| 20/07/26 | R$57.90 | -0.31% | 5 |
| 17/07/26 | R$58.08 | +0.75% | 365 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- REGN Stock
- REGN34 Stock
Select your edition
All financial news and data tailored to specific country editions
